Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Recruiting · NCT06279351 · Interventional (participants receive a specific treatment) · Lead sponsor: Xinqiao Hospital of Chongqing
View the official record on ClinicalTrials.gov →Interventions studied
Thalidomide+cetuximab+FOLFOX/FOLFIRI
What this trial is about
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application. 2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
- Physical state is good: PS 0-2;
- Expected survival of more than 3 months;
- Aged 18-75 years old;
- Have not received systematic chemotherapy before;
- Did not receive cetuximab treatment;
- Liver, kidney and bone marrow functions are basically normal;
- The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;
- Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.
Exclusion criteria
- Patients with severe dysfunction of vital organs (heart, liver, kidney);
- Patients with other malignant tumors;
- Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);
- In the active phase of acute or chronic infectious diseases;
- People with a clear history of drug allergy or allergic constitution;
- Patients participating in other clinical trials;
- Other conditions in which the patient was considered inappropriate to participate in the study.
Where it is running
1 location listed.
- the second affiliated hospital of Army medical university - Chongqing, Chongqing Municipality, China